Title |
Deprivation of arginine by recombinant human arginase in prostate cancer cells
|
---|---|
Published in |
Journal of Hematology & Oncology, April 2012
|
DOI | 10.1186/1756-8722-5-17 |
Pubmed ID | |
Authors |
Eddy C Hsueh, Stephanie M Knebel, Wai-Hung Lo, Yun-Chung Leung, Paul Ning-Man Cheng, Chung-Tsen Hsueh |
Abstract |
Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly, a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are sensitive to arginine deprivation by arginine deiminase. In this study, we investigated levels of gene expression of OCT and ASS, and the effects of rhArg in human prostate cancer cells: LNCaP (androgen-dependent), PC-3 and DU-145 (both androgen-independent). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Czechia | 1 | 1% |
Unknown | 65 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 16 | 24% |
Researcher | 11 | 16% |
Student > Master | 8 | 12% |
Student > Bachelor | 4 | 6% |
Student > Doctoral Student | 4 | 6% |
Other | 10 | 15% |
Unknown | 14 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 16 | 24% |
Biochemistry, Genetics and Molecular Biology | 14 | 21% |
Medicine and Dentistry | 9 | 13% |
Chemistry | 3 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 7 | 10% |
Unknown | 16 | 24% |